Market News How it works Learn FAQ
| AXG 0.0378 -29.74% | SHFS 0.1113 18.40% | DVLT 0.069 -48.04% | XXII 0.1022 15.61% | NEXR 0.5454 21.77% | SOFI 16.4 13.42% | WFF 0.0601 -33.07% | NU 12.4 -1.51% | NVD 3.93 -1.50% | SPCX 148.58 1.14% | SOXL 101.08 11.69% | EWZ 34.3 0.45% | INTC 93.74 3.61% | NVDA 217.94 0.90% | BBD 2.91 -0.51% | SOXS 42.495 -11.43% | JBLU 2.82 18.99% | GRAB 2.72 0.37% | GPUS 0.2126 19.10% | VALE 11.84 -1.33% | SNTI 0.1867 6.62% | NOK 8.89 3.30% | HYG 77.6 0.52% | AAL 12.61 3.36% | BITO 10.79 1.27% | CRWV 59.57 7.94% | TSLL 11.63 8.09% | RCT 0.0632 -23.58% | META 620.19 -1.64% | TQQQ 71.05 3.83% | QID 13.86 -2.53% | STLA 4.14 1.47% | NFLX 62.52 -2.16% | TSLG 5.82 8.18% | BA 168.18 -10.69% | IREN 27.44 7.90% | T 20.94 0.46% | PLUG 1.4 2.19% | BRAI 3.31 56.13% | TSLA 407.46 4.04% | CIFR 8.48 9.99% | ONDS 6.65 7.95% | RWM 14.34 -1.10% | F 11.71 1.12% | RIG 6.46 -1.07% | XP 15.96 1.62% | ITUB 7.67 -0.39% | SNAP 6.06 -4.42% | KORU 11.85 8.82% | WULF 12.66 5.68%
IRIronwood Pharmaceuticals, Inc. logo

Ironwood Pharmaceuticals, Inc. (IRWD)

NASDAQ Global Select · Currency in USD
$3.51 ▲ +0.01 (+0.29%)
At close: Oct 27, 4:00 PM ET. Market closed.
$3.51 ▲ +0.00 (+0.00%)
After hours: Oct 27, 4:10 PM ET

Summary

Previous Close
$3.50
Open
$3.52
Day's Range
$3.45 – $3.55
52 Week Range
$1.47 – $5.78
Volume
1,655,126
Avg. Volume
2,141,291
Market Cap
$579.99M
Beta (5Y Monthly)
0.22
PE Ratio (TTM)
4.41
EPS (TTM)
$0.78
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$6.68

Profile: Ironwood Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full-time employees
100
CEO
Thomas A. McCourt

Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union.

Earnings

Next report: Mon, Nov 9, 2026
EPS estimate $0.32 · Revenue est. $119.99M
DateEst.Actual
Aug 6, 2026$0.32$0.31Miss
May 7, 2026$0.07$0.24Beat
Feb 25, 2026$0.02-$0.01Miss
Nov 10, 2025$0.09$0.24Beat
Aug 7, 2025-$0.02$0.14Beat
May 7, 2025-$0.05-$0.23Miss

Analyst view

Consensus price target
$6.68 ▲ +90.3%
Range $1.00 – $18.00
Rating: Hold
Buy 37% · Hold 53% · Sell 10%

Similar stocks

Get free alerts on IRWD and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.